News

Abbott has entered into an agreement with GlaxoSmithKline (GSK) to develop an automated molecular diagnostic test, based on polymerase chain reaction technology. The test is intended to screen

Inovio’ SynCon H1N1 influenza DNA vaccines has achieved protective antibody responses against H1N1 swine influenza virus, in 100% of pigs immunized with a two-dose vaccine regimen. In the

Oculus Innovative Sciences (OCLS) has entered into an agreement with OroScience. As per the agreement, OroScience was granted exclusive rights to market Microcyn-based oral products in the US,

Cornerstone Therapeutics has signed an asset purchase agreement with Oscient to acquire the commercial rights to the antibiotic – Factive (gemifloxacin mesylate), in North America and certain countries

Humanetics has announced that the results of a preliminary phase IIA clinical trial suggest that a new Alzheimer’s drug NIC5-15, is safe for daily use and that cognitive

MacroGenics has initiated Paradigm trial, a phase 2 clinical study evaluating MGAWN1. MGAWN1 is a humanized monoclonal antibody, for the treatment of individuals with suspected central nervous system

SOCMA has commended the US Senate for approving legislation that would extend existing chemical security standards for one more year. Reportedly, the Senate voted 84-6 on July 9

Rexahn Pharmaceuticals has entered into a licensing partnership with Korea Research Institute of Chemical Technology (KRICT). The deal is regarding the development of a synthetic process for Quinoxalines

AxoGen is beginning full distribution of Avance Nerve Graft. Its a proprietary human tissue product for use in the reconstruction of damaged peripheral nerves to all surgeons who